Introduction {#sec1-2331216514541361}
============

Among the many causes of hearing loss, viruses often are ignored. Viral infections, in particular cytomegalovirus (CMV), cause up to 40% of all congenitally acquired hearing loss. Many viruses can be the cause of congenital or acquired hearing loss ([Table 1](#table1-2331216514541361){ref-type="table"}). Typically, viruses cause sensorineural hearing loss (SNHL); however, a viral etiology has been proposed for otosclerosis. Infection with HIV can lead to conductive hearing loss (CHL) through bacterial and fungal infections, which become more frequent following the immunosuppression caused by that virus. Hearing loss caused by viruses can be mild or severe to profound, unilateral or bilateral. Mechanisms involved in the induction of hearing loss by different viruses vary greatly, ranging from direct damage to inner ear structures, including inner ear hair cells and organ of Corti (as seen in some of the classically described causes of viral hearing loss such as measles), to induction of host immune-mediated damage ([Table 2](#table2-2331216514541361){ref-type="table"}). Following infections with certain viruses, hearing loss can be reversed or limited by appropriate antiviral therapy. Effective vaccines are available for many of the viruses that cause hearing loss, leading to substantial changes in the incidence of these infections and to their prevalence as causes of hearing loss. Although it may seem a daunting task, a working knowledge of the potential viral causes of hearing loss and their treatment is essential to the recognition of these entities and their appropriate management. Table 1.Viral Causes of Hearing Loss.VirusType of HLDegree of HLIncidence of HLPreventionTreatmentHearing recoveryCongenital CMVBilateral progressive SNHLSevere6--23% if asymptomatic; 22--65% if symptomaticNoneGanciclovir, valganciclovir, cidofovir, foscarnetOnly with antiviral therapy RubellaBilateral SNHLMild to severe12--19%MMRNoneNone LCMVBilateral SNHLSevere to profound7.4%Avoidance of exposureRibavirin, favipiravirNoneCongenital and acquired HIVSNHL, CHL, mixedSNHL: mild to moderate; CHL: mild to maximal27.5--33.5%Postexposure antiretroviralHAARTDependent on type of HL HSVUnilateral or bilateral SNHLModerate to profoundUp to 33% (congenital)NoneAcyclovirNoneAcquired MeaslesBilateral SNHLProfound0.1--3.4%MMR, IVIgNoneNone VZVUnilateral SNHLMild to moderate7--85%ZostavaxAcyclovir, prednisoneImproves with Rx MumpsUnilateral SNHLVariable0.005--4%MMRNoneSpontaneous WNVBilateral SNHLMild to profoundRareVaccine in trialsNoneSpontaneous[^1] Table 2.Potential Etiologies of Hearing Loss Due to Different Viral Infections.VirusDirectIndirectUnknownStria vascularisOrgan of CortiNeuronal (cochlear, central)Decreased immunity and secondary infectionHost immune response to viral antigenCMV**x**LCMV**x**HIV**xxx**HSV**x**Rubeola^a^**xx**Mumps**xxx**Rubella**xx**WNV**x**VZV**x**[^2][^3]

In this review, we discuss many of the common viral causes of hearing loss and the interventions available for their prevention and treatment. Viruses causing congenital hearing losses are discussed first, followed by those that cause both congenital and acquired hearing loss, and finally those that exclusively cause acquired hearing loss. Within each category, the most common viral causes of hearing loss are discussed first, and then infrequent or emerging viruses that have been shown to cause hearing loss are discussed.

Viruses Causing Congenital Hearing Loss {#sec2-2331216514541361}
=======================================

Cytomegalovirus {#sec3-2331216514541361}
---------------

CMV is an extremely common viral infection with nearly 100% prevalence. Despite its high prevalence, CMV rarely causes symptomatic disease in immunocompetent older infants or adults. CMV is a member of the herpesvirus family, along with herpes simplex virus (HSV), varicella zoster virus (VZV), and Epstein--Barr virus. Like all herpesviruses, CMV is a double-stranded enveloped DNA virus that can remain latent in the body long after primary infection. CMV can reactivate and cause disease in immunocompromised hosts. During reactivation, the virus again begins to make copies of its DNA and transmission to other people can occur.

CMV is typically acquired early in life and may be acquired in utero. In the United States, up to 1% of newborns are infected ([@bibr36-2331216514541361]; [@bibr66-2331216514541361]; [@bibr102-2331216514541361]). CMV transmission to fetuses can occur during primary maternal infection (accounting for 40--50% of cases of congenital CMV) or reactivation during pregnancy (1% of cases of congenital CMV) ([@bibr2-2331216514541361]; [@bibr8-2331216514541361]). Congenitally acquired CMV is included as one of the TORCHS, an acronym for frequently occurring infectious teratogens (toxoplasmosis, rubella, CMV, herpes simplex, and syphilis, respectively). All of the TORCHS infections can cause similar signs before and after birth as well as similar birth defects. These include reduced intrauterine growth, microcephaly, seizures, mental retardation, visual defects, and cerebral palsy ([@bibr66-2331216514541361]; [@bibr102-2331216514541361]). Overall, the TORCHS are one of the most common causes of hearing loss that lead to pediatric cochlear implantation ([@bibr102-2331216514541361]).

Maternal infection with CMV earlier in pregnancy increases the risk of symptomatic infection ([@bibr8-2331216514541361]; [@bibr87-2331216514541361]). Only 5% to 10% of infected neonates will show signs of CMV infection at birth ([@bibr36-2331216514541361]). Among these symptomatic infants, mortality is high (5%), and infants who survive often have permanent neurological defects such as SNHL, visual deficits, and seizures ([@bibr8-2331216514541361]).

CMV is the leading nongenetic cause of childhood SNHL. Hearing loss can occur in both symptomatic and asymptomatically infected children. Delayed manifestations of congenital CMV infection, particularly SNHL, can manifest months or years after birth ([@bibr36-2331216514541361]). Initial hearing screens will miss the majority of cases of SNHL in CMV-infected children ([@bibr35-2331216514541361]). The average age of diagnosis of hearing impairment in congenitally infected children is 27 to 33 months. Hearing loss may be diagnosed many years later, and thus CMV may be the cause underlying many cases of idiopathic SNHL in children ([@bibr36-2331216514541361]; [@bibr42-2331216514541361]). Of children born with symptomatic CMV infection, 14% will develop hearing loss and 5% will have severe, bilateral SNHL ([@bibr42-2331216514541361]). Risk factors for the development of SNHL in initially asymptomatic CMV-infected infants have not been identified, and so periodic screening of infected children is necessary ([@bibr9-2331216514541361]; [@bibr35-2331216514541361]; [@bibr102-2331216514541361]). The etiology of SNHL resulting from CMV infection is not fully understood. Temporal bone studies demonstrate inflammation and edema of the cochlea and spiral ganglion, and viral antigens in the spiral ganglion, organ of Corti, scala media, and Reissner's membrane ([@bibr36-2331216514541361]; [@bibr95-2331216514541361]; [Figure 1](#fig1-2331216514541361){ref-type="fig"}). Whether damage to inner ear structures is due to the direct effects of the virus or the innocent bystander effects of the patient's immune system reacting to the presence of viral antigens in these areas is still an area of active research. Recent research in a guinea pig model system demonstrates that CMV expresses proteins that trigger an immune response that leads to hearing loss and inflammation within the cochlea ([@bibr95-2331216514541361]). This theory of pathogenesis may not fully explain progressive or later onset hearing losses seen in patients following CMV infection in utero. Figure 1.Temporal bone histology of guinea pigs either mock infected (a,b) or infected with CMV (c,d).*Note.* Inflammatory cells and early fibrosis are found within the scala tympani in animals infected with CMV (arrows).Source: Temporal bone pathology used with permission from Schraff et al. (2007).

The presentation, severity, progression, and audiographic pattern of SNHL resulting from congenital CMV infection are highly variable ([@bibr36-2331216514541361]; [@bibr42-2331216514541361]). Following identification of SNHL in children with CMV, continued audiographic monitoring is necessary due to frequent progression ([@bibr9-2331216514541361]; [@bibr33-2331216514541361]). Generally, SNHL in children with initially asymptomatic CMV infections involves high frequencies and fluctuates. Hearing loss in children who were initially symptomatic tends to be bilateral, more severe, and more likely to progress ([@bibr34-2331216514541361]; [@bibr66-2331216514541361]).

Ganciclovir is the treatment for both early and delayed SNHL resulting from congenital CMV infection. Ganciclovir prevents SNHL progression and sometimes can improve hearing status. This medication must be administered intravenously and can be associated with neutropenia ([@bibr59-2331216514541361]). Other options include valganciclovir (a prodrug of ganciclovir that can be given orally), cidofovir, and foscarnet. Studies are currently underway testing the efficacy and duration of treatment of infected neonates with valganciclovir ([@bibr101-2331216514541361]). Ganciclovir is teratogenic in animal studies and so cannot be used to treat pregnant women with active CMV infection. Other treatment modalities also exist. In vitro and animal studies support the use of CMV hyperimmune globulin during pregnancy ([@bibr15-2331216514541361]). SNHL that does not respond to antiviral medications can be treated with hearing aids or cochlear implantation depending on hearing severity. Cochlear implantation can significantly improve hearing loss due to CMV infection; however, the extent of improvement in speech and language skills following cochlear implantation may not be as great as in non-CMV-infected children with severe to profound hearing loss ([@bibr101-2331216514541361]).

Despite multiple attempts at vaccine development, there is not currently an effective CMV vaccine. Prevention of primary infection in previously uninfected pregnant women is therefore the mainstay of limiting congenital CMV infection. Pregnant women are encouraged to frequently wash their hands and to avoid contact with saliva or urine of children younger than 6 years, particularly if they are enrolled in daycare. The U.S. Centers for Disease Control and Prevention (CDC) does not advocate CMV screening due to concerns that CMV IgM testing is not sufficiently specific and because treatment of CMV during pregnancy is controversial ([@bibr15-2331216514541361]).

Rubella {#sec4-2331216514541361}
-------

Rubella, also known as the German measles, is a member of the *Togaviridae* family of viruses. The genome of this virus is a single-stranded RNA and is enclosed in an icosahedral nonenveloped capsid. Rubella is most commonly transmitted via contaminated upper respiratory secretions during coughing, sneezing, and talking. In immunocompetent adults, the virus has a self-limiting course marked by low-grade fever, eye pain with movement, conjunctivitis, sore throat, malaise, headache, nausea, decreased appetite, transient arthritis, and tender lymphadenopathy ([@bibr64-2331216514541361]; [@bibr72-2331216514541361]). In contrast, if the virus is acquired during pregnancy it is a potent teratogen and one of the TORCHS infections ([@bibr72-2331216514541361]). Congenital rubella syndrome manifests as hearing loss, congenital cataracts, microcephaly, mental retardation, thrombocytopenia, cardiac anomalies, and a characteristic rash (the so-called blueberry muffin spots; [@bibr85-2331216514541361]).

SNHL is the most common sequela of congenital rubella infection (58%) and is most often seen when maternal rubella infection occurs within the first 16 weeks of pregnancy. Vestibular function is spared ([@bibr125-2331216514541361]). Hearing loss typically manifests in the first 6 to 12 months of life, although it can present at birth ([@bibr22-2331216514541361]; [@bibr27-2331216514541361]). Audiograms often show a flat, uniform mild to severe SNHL, but isolated high-frequency hearing loss has been reported ([@bibr22-2331216514541361]; [@bibr100-2331216514541361]).

While the mechanism of rubella-induced hearing loss has not been fully explained, the virus causes direct cochlear damage and cell death in the organ of Corti and stria vascularis ([@bibr64-2331216514541361]). Alterations in the composition of endolymph due to strial damage have also been described ([@bibr125-2331216514541361]). Depending on the severity of hearing loss, treatment options include the use of hearing aids and cochlear implantation ([@bibr102-2331216514541361]).

Vaccination of women prior to or during reproductive age is extremely effective at prevention of congenital rubella in their offspring ([@bibr25-2331216514541361]). In areas without routine rubella vaccination, congenital rubella remains a common cause of severe to profound bilateral SNHL. In a recent Brazilian study, congenital rubella was thought to be the cause of hearing loss in 32% of patients with deafness ([@bibr23-2331216514541361]). Following the institution of a "school girl" vaccination program in Western Australia, the rate of congenital rubella syndrome dropped to 0% in vaccinated mothers ([@bibr103-2331216514541361]). Despite vaccination, however, rare cases of congenital rubella syndrome have been documented, delivered to previously vaccinated mothers who had received only one dose of the vaccine ([@bibr73-2331216514541361]). There is also one published case of bilateral profound hearing loss occurring in an adult following measles--rubella vaccination that has been attributed to rubella infection from the vaccine strain, although this was not confirmed by isolation of the virus ([@bibr50-2331216514541361]).

The U.S. CDC recommends rubella vaccination at age 12 to 15 months of age with a booster at 4 to 6 years, given as a part of the combined measles, mumps, and rubella (MMR) vaccine. Since the vaccine contains an attenuated live form of rubella, it should not be used to vaccinate during or 1 month prior to planned pregnancy ([@bibr72-2331216514541361]). Published cases of accidental vaccination during pregnancy yielded no cases of congenital rubella syndrome, although 4.5% of children had serologic evidence of rubella infection ([@bibr30-2331216514541361]; [@bibr79-2331216514541361]; [@bibr93-2331216514541361]). If a woman not known to be pregnant is vaccinated, no intervention is currently recommended. Congenital rubella syndrome has not been reported following birth from mothers who were asymptomatically infected during pregnancy. Due to successful vaccination programs, rubella is currently considered eliminated in the United States; however, cases can still occur due to importation of the infection from other countries ([@bibr72-2331216514541361]).

Lymphocytic Choriomeningitis Virus {#sec5-2331216514541361}
----------------------------------

Lymphocytic choriomeningitis virus (LCMV) is a single-stranded enveloped RNA virus. LCMV is a member of the *Arenaviridae* family and has been identified as an emerging teratogen ([@bibr10-2331216514541361]). Rodents, including the common house mouse, are the natural hosts and serve as reservoirs of LCMV ([@bibr52-2331216514541361]). Infection is transmitted to humans through contact with rodent urine, feces, or saliva, and occurs more commonly in winter months when mice seek shelter indoors ([@bibr11-2331216514541361]). The virus is not typically spread between humans; however, there have been cases of transmission via organ transplantation ([@bibr52-2331216514541361]).

In immunocompetent adults, LCMV infection is typically either asymptomatic or associated with upper respiratory tract infection symptoms (fever, headache, nausea, and vomiting). Rarely, complications such as aseptic meningitis and meningoencephalitis occur. LCMV infection in pregnancy greatly increases the risk of spontaneous abortion. LCMV infection can also be teratogenic, especially if the virus is contracted during the first or second trimester, and is associated with microcephaly, hydrocephalus, ventriculomegaly, pachygyra, cerebellar hypoplasia, chorioretinitis, periventricular calcification, and hearing loss ([@bibr5-2331216514541361]; [@bibr11-2331216514541361]; [@bibr52-2331216514541361]; [Figure 2](#fig2-2331216514541361){ref-type="fig"}). In contrast to congenital CMV or rubella, visual impairment and microcephaly are much more common than hearing loss in congenital LCMV infection. LCMV can also be distinguished from these other congenital viral causes of hearing loss by the lack of hepatosplenomegaly ([@bibr10-2331216514541361]). Figure 2.Fetal (28 weeks gestation) (a) and postnatal (week of life 1) (b) MRI of infant with congenital LCMV infection, demonstrating severe ventriculomegaly (asterisks).*Note.* The patient had severe growth and developmental delays, mild myopia with chorioretinopathy, profound hearing loss on the left side, and severe loss of hearing on the right.Source: MRI images used with permission from [@bibr5-2331216514541361].

Enzyme-linked immunosorbent assay (ELISA) for LCMV IgG and IgM antibodies can establish the diagnosis of congenital LCMV infection. Hearing loss in these patients is relatively rare, can vary in severity between ears, and ranges from severe to profound SNHL ([@bibr5-2331216514541361]; [@bibr10-2331216514541361]).

Ribavirin, a nucleoside inhibitor used to stop viral RNA synthesis and capping, has been used to treat LCMV infection in adults. However, ribavirin efficacy against LCMV has not been proven in clinical trials and is associated with significant side effects such as hemolytic anemia. Ribavirin is a teratogen in many animal models and should not be used to treat pregnant women ([@bibr52-2331216514541361]). Favipiravir, an antiviral drug that may target RNA-dependent RNA polymerase and is therefore effective against a wide range of RNA viruses, may be a future treatment option but at present has only been tested against LCMV in vitro ([@bibr11-2331216514541361]).

Treatment of hearing loss in affected children with hearing aids and other assistive listening devices is indicated when appropriate. Treatment of severe to profound SNHL in children with congenital LCMV may be limited in patients in whom involvement of the vestibulocochlear nerve is the cause of hearing loss; however, because severe visual impairment is seen in all children with congenital LCMV infection, it should be attempted.

Viruses Causing Congenital and Acquired Hearing Loss {#sec6-2331216514541361}
====================================================

Human Immunodeficiency Virus {#sec7-2331216514541361}
----------------------------

HIV is the retrovirus that causes AIDS. HIV is composed of a single-stranded RNA genome, which is converted to double-stranded DNA after infection of the host cell. HIV can infect a wide range of cell types but preferentially infects neurons and immune cells, particularly CD4+ T-cells. Over time, death of helper T-cells results in immunosuppression, with resultant development of opportunistic infections and cancers ([@bibr88-2331216514541361]).

Symptoms of the initial infection are nonspecific and include fever, headache, sore throat, and myalgias. As the disease progresses and immune deficiency develops, patients develop opportunistic infections and other manifestations of HIV in multiple organ systems. Common symptoms within the temporal bone include hearing loss, tinnitus, chronic otitis media, facial nerve palsy, and malignancies ([@bibr84-2331216514541361]; [@bibr88-2331216514541361]; [@bibr91-2331216514541361]).

The prevalence of auditory symptoms in patients with HIV is 14% to 49% ([@bibr18-2331216514541361]; [@bibr68-2331216514541361]; [@bibr91-2331216514541361]; [@bibr119-2331216514541361]). In a study of 200 HIV-positive South African adults, many patients complained of hearing loss (27.5%) and vertigo (25%; [@bibr119-2331216514541361]). Audiograms performed in a 1997 U.S. study of 99 HIV-positive patients detected significant hearing loss in 29%. The risk of developing hearing loss increases with the patient's age after the third decade of life ([@bibr68-2331216514541361]). Infants can develop hearing loss following either infection or exposure in utero without infection ([@bibr116-2331216514541361]). In a study of 370 HIV-positive children in Uganda (mean age 38 months, range 6 months to 5 years), 33% developed hearing loss. Two-thirds of the children with hearing loss in this study had SNHL ([@bibr19-2331216514541361]).

Hearing loss associated with HIV infection can be unilateral or bilateral, progressive or sudden, and conductive, sensorineural, or mixed. Hearing loss in HIV-infected patients can be caused by a number of factors, including the direct effects of HIV, increased susceptibility to opportunistic infections in the middle ear and brain, and treatment with potentially ototoxic medications (Khoza-Shangase et al., 2011). CHL often results from recurrent otitis media, otitis externa, acquired aural atresia, cholesteatoma, formation of aural polyps, or malignancy ([@bibr91-2331216514541361]). SNHL is more common in adults and can have a variety of causes, including direct damage to the auditory system by HIV, opportunistic infections, and ototoxicity. SNHL can occur early in the course of HIV infection, even in the absence of prior treatment with antivirals or depression of CD4 counts ([@bibr69-2331216514541361]). Rarely, SNHL may be the only presenting symptom of HIV infection ([@bibr114-2331216514541361]). Typically, SNHLs are mild to moderate and predominantly include high frequencies ([@bibr18-2331216514541361]; [@bibr119-2331216514541361]). Severity of hearing loss has been correlated with disease progression and decline in CD4 counts ([@bibr119-2331216514541361]). This might lead some to suspect that hearing loss in patients with HIV might be prevented by antiretroviral therapy. However, hearing loss is still seen at higher levels in patients treated with highly active antiretroviral therapy (HAART) than in controls ([@bibr89-2331216514541361]).

A variety of studies have demonstrated that HIV may affect the auditory system both centrally and peripherally. HIV has been detected in auditory and vestibular hair cells, strial cells, and along the tectorial membrane ([@bibr86-2331216514541361]). However, patients with HIV have abnormal brainstem responses (ABRs), suggesting involvement of the auditory nerve ([@bibr41-2331216514541361]; [@bibr91-2331216514541361]). SNHL may occur in patients with HIV as the result of increased vulnerability to other pathogens, such as syphilis, CMV, HSV, toxoplasmosis, and herpes zoster oticus (HZO), or as a result of the ototoxic medications used to treat these conditions. Because SNHL in patients with HIV may be caused by other infections as well as primary effects of HIV itself, computed tomography (CT) or magnetic resonance imaging (MRI) should be performed to rule out other central nervous system infections ([@bibr61-2331216514541361]; [@bibr116-2331216514541361]). Because HIV-positive patients often present with multiple risk factors for hearing loss, it can be impossible to ethically determine the exact etiology of the observed hearing losses. Thus, development of an animal model for these studies would significantly improve understanding of the direct role of HIV in hearing loss.

HIV prevention is predominantly guided by avoidance of contact with infected blood and bodily secretions. Use of antiretroviral cocktails reduces HIV transmission from infected mothers to fetuses and breastfeeding children from 25% to 48% to 1% to 2% ([@bibr108-2331216514541361]). Two- or three-drug antiviral regimens initiated as soon as possible (ideally within 24--36 hr) after accidental exposure to HIV-infected body fluids also greatly decreases the risk of HIV infection ([@bibr115-2331216514541361]). The use of HAART has dramatically improved morbidity and mortality associated with HIV infection. By increasing CD4+ T-cell counts, HAART can protect patients from opportunistic infections that can cause hearing loss. HAART use does not significantly reverse hearing loss, and one study suggested a positive correlation between hearing loss and use of antiretroviral medications in patients older than 35 years ([@bibr68-2331216514541361]). However, a prospective observational study of hearing loss in patients treated with either zidovudine or didanosine concluded that antiretroviral therapy is not detrimental to hearing ([@bibr94-2331216514541361]).

Hearing aids can be used in the treatment of HIV-infected patients with mild to moderate SNHL. For patients with severe to profound SNHL, cochlear implantation can be successful ([@bibr121-2331216514541361]). In HIV-positive patients with stable CD4 counts, otologic surgery can be performed without additional operative risks and have favorable results ([@bibr60-2331216514541361]; [@bibr117-2331216514541361]). Following cochlear implantation, these patients should be closely followed to avoid development of chronic otitis media and its related complications ([@bibr121-2331216514541361]). Chronic otitis media and cholesteatoma in HIV-infected patients can be successfully surgically treated as well ([@bibr60-2331216514541361]). However, in our experience, treatment of acquired canal atresias in HIV-infected patients has at least up to a 50% rate of late restenosis, even when CD4+ T-cell counts are stable on HAART; skin grafts, canalplasty, and meatoplasty are performed; and close follow-up with rapid treatment of otitis externa is maintained.

HSV Types 1 and 2 {#sec8-2331216514541361}
-----------------

HSV types 1 and 2 have been implicated as causes of hearing loss. Both are encapsulated, double-stranded DNA viruses of the herpesvirus family. Infection follows contact of mucous membranes or broken skin surfaces with infected fluids from herpes sores or with other body fluids of patients with herpes. The initial infection may be asymptomatic or can be associated with symptoms. For HSV1, these symptoms can include painful blisters on the lips and tongue that eventually rupture, dysphagia, fever, myalgias, and sore throat. In the case of HSV2 primary infection, symptoms include tingling in the affected areas, followed by an erythematous papular rash that evolves into blisters and then ruptured open lesions, as well as a viral prodrome and headache. The viruses can latently infect nerve cells innervating the initially infected tissue. Months to years later, the viruses can reactivate, leading to recurrent disease. HSV type 1 is typically associated with labial herpes and type 2 with genital herpes, although either virus can infect and manifest in the other's typical territory ([@bibr129-2331216514541361]).

Congenital herpes infection typically arises due to exposure to HSV1 or HSV2 during delivery. Neonatal infection is more frequent from women who develop infection late during pregnancy or who have active herpetic lesions in the birth canal. However, 30% of pregnant women without prior history of HSV2 may be serologically positive and have asymptomatic viral shedding, which can lead to neonatal infection. Many (62%) of HSV2-infected mothers are HSV1 positive as well. Neonatal HSV1 infection occurs in 1/2,000 to 1/8,000 and HSV2 in 5.9/100,000 live births ([@bibr76-2331216514541361]; [@bibr127-2331216514541361]). Sequelae of neonatal infection range from eye and mucous membrane involvement to disseminated disease, encephalitis, hearing loss, mental retardation, microcephaly, and death. Many infected infants will not have a vesicular rash and so may not be tested for HSV infection (reviewed in [@bibr127-2331216514541361]).

HSV1 infection is much more frequently associated with encephalitis and hearing loss following infection in neonates compared with HSV2 ([@bibr4-2331216514541361]). However, hearing loss following HSV1 infection is relatively rare and typically associated with concomitant severe neurological complications. Hearing loss following neonatal infection can be bilateral or unilateral severe to profound SNHL ([@bibr127-2331216514541361]). One case series described four children with mild to moderate SNHL on ABRs but severe auditory agnosia and bilateral auditory cortex lesions on MRI after herpes encephalitis ([@bibr55-2331216514541361]).

HSV1 infection has also been associated with hearing loss following infection or reactivation of latent infection after infancy. Some of these cases are associated with herpes simplex meningitis or encephalitis. Hearing loss in this setting is bilateral and severe ([@bibr63-2331216514541361]; [@bibr74-2331216514541361]; [@bibr75-2331216514541361]; [@bibr90-2331216514541361]). In one case, a 3-year-old boy suddenly developed a profound bilateral hearing loss following a mild febrile illness. IgG and IgM were positive for HSV1 and indicative of primary infection. He was treated with prednisone and acyclovir with partial recovery of hearing ([@bibr17-2331216514541361]). In another report, a 61-year-old woman who developed oral herpes lesions and subsequent bilateral profound hearing loss had no recovery of hearing following treatment with prednisone and acyclovir. Her serological testing was consistent with HSV1 reactivation ([@bibr90-2331216514541361]).

Animal studies have confirmed that herpes simplex infections can cause hearing loss and vestibular symptoms. Following infection with HSV1 or HSV2, fibrosis of the scala tympani and vestibule, loss of outer hair cells, and atrophy of the stria vascularis and tectorial membrane were found in these animals. Viral antigens were located throughout the cochlea, and viral capsids were found within cochlear nerve fibers, including both afferent and efferent nerve endings. These findings were similar to those found in human temporal bone studies of patients with deafness following known viral infection with measles or rubella ([@bibr82-2331216514541361]). When treated with acyclovir and steroids, animals infected with HSV had less severe hearing loss and decreased damage to intracochlear structures than untreated, infected animals ([@bibr105-2331216514541361]). In all of these animal studies, temporal bone changes induced by HSV infection were similar to those seen in humans with sudden SNHL (SSNHL; [@bibr31-2331216514541361]; [@bibr82-2331216514541361]; [@bibr105-2331216514541361]).

HSV1 and HSV2 have been associated with SSNHL in some, but not all, human studies in which testing for these viruses following onset of hearing loss has been performed ([@bibr39-2331216514541361]; [@bibr62-2331216514541361]; [@bibr110-2331216514541361]; [@bibr120-2331216514541361]; [@bibr130-2331216514541361]; [@bibr132-2331216514541361]). Additionally, HSV1 has been suggested as the etiologic agent in Meniere's disease, although not all studies support this association ([@bibr6-2331216514541361]; [@bibr14-2331216514541361]; [@bibr40-2331216514541361]; [@bibr97-2331216514541361]; [@bibr113-2331216514541361]; [@bibr122-2331216514541361]; [@bibr126-2331216514541361]; [@bibr131-2331216514541361]). A randomized placebo controlled trial of the use of famciclovir, an antiherpetic agent, for patients with Meniere's disease found a trend toward reduction in hearing fluctuation but no difference in number of episodes of dizziness that these patients experienced ([@bibr26-2331216514541361]).

There currently are no approved vaccines for HSV1 or HSV2. Prevention of neonatal HSV infection can be achieved by preventing transmission of herpes simplex from infected mothers to their infants during delivery. Women with primary HSV1 or HSV2 contracted during pregnancy should be treated with 400 mg of oral acyclovir three times a day (TID) for 7 to 10 days, regardless of the timing of the occurrence. In addition, the American College of Obstetricians and Gynecologists recommends herpes suppressive therapy for these women from 36 weeks gestation to delivery. Similarly, women with recurrent herpes should receive herpes suppressive therapy from 36 weeks until delivery. Cesarean delivery is recommended for women with active herpes lesions at the time of delivery ([@bibr51-2331216514541361]).

Treatment of hearing loss associated with HSV1 or HSV2 infections includes treatment with antiherpetic agents and steroids. In the setting of encephalitis and hearing loss, standard therapy for HSV1 encephalitis (10--15 mg/kg acyclovir TID) should be performed; in the setting of meningitis and hearing loss, therapy for HSV1 meningitis may be adequate (5--10 mg/kg acyclovir TID or valacyclovir 1,000 mg TID; [@bibr107-2331216514541361]). Hearing loss that does not recover following treatment with steroids and antiherpetic agents can be remediated with hearing aids or cochlear implantation, depending on the severity of loss.

Viruses Causing Acquired Hearing Loss {#sec9-2331216514541361}
=====================================

Measles (Rubeola) {#sec10-2331216514541361}
-----------------

The measles virus (rubeola) is an enveloped single-stranded RNA virus in the paramyxovirus family. It is very easily transmitted through contact with respiratory secretions from patients with measles. Symptoms include fever, cough, nasal congestion, erythematous maculopapular rash, conjunctivitis, and pathognomonic Koplik spots on the buccal mucosa. Hearing loss is a common complication of measles infection; prior to widespread vaccination, measles accounted for 5 to 10% of cases of profound hearing loss in the United States ([@bibr71-2331216514541361]). In 2000, measles was declared eliminated from the United States, although cases resulting from immigration or importation of the virus continue to occur ([@bibr72-2331216514541361]). Measles continues to be a common cause of profound hearing loss in areas in which measles vaccination is rare ([@bibr28-2331216514541361]).

Fortunately, most children recover from measles without long-term side effects. However, due to measles' virulence, it was a nearly ubiquitous viral infection of childhood prior to the development of vaccines, and so complications that appear to be infrequent on a percentage based on the total number of individuals infected actually affected a large number of people. Prior to the effective vaccination, measles was thought to be the cause of severe to profound hearing loss in 4% to 9% of deaf patients ([@bibr109-2331216514541361]). Hearing loss resulting from measles infection is typically bilateral, moderate to profound SNHL and may follow measles encephalitis ([@bibr71-2331216514541361]). Temporal bone studies on infected humans and in animal models have shown degeneration of cochlear neurons most prominently in the basal turn, degeneration of the organ of Corti and stria vascularis, and cellular infiltration of the cochlea ([@bibr37-2331216514541361]; [@bibr71-2331216514541361]; [@bibr109-2331216514541361]). Measles is associated with a high incidence of otitis media (in up to 8.5--25% of infected people, higher in developing countries), possibly due to a transient decrease in the immune response to infection ([@bibr104-2331216514541361]). Sequelae of bacterial superinfection may account for some cases of hearing loss associated with measles infection ([@bibr109-2331216514541361]).

The mainstay of measles prevention is through MMR vaccination, with the first dose at age 12 to 15 months and the second at 4 to 6 years of age (the third dose of MMR in the teens/early twenties is indicated for prevention of mumps). Prior to the development of widespread vaccination, measles would infect \>90% of susceptible children in epidemics. Compilation of infection data from multiple countries shows 70.9 cases of rubeola/100,000 unvaccinated people compared with 0.9 cases/100,000 people in countries in which 90% to 100% of the target population of children had received just one dose of measles vaccine ([@bibr44-2331216514541361]). As noted previously, MMR includes live-attenuated measles virus, and so cannot be used in immunocompromised patients, although recent guidelines have been revised to recommend MMR vaccination in patients aged ≥12 months with HIV who do not have severe immunosuppression ([@bibr72-2331216514541361]). MMR and other anti-measles vaccinations are rarely associated with SNHL, with a time course of onset corresponding to incubation period of measles infection and an incidence of 1 case per 6 to 8 million vaccine doses. Because MMR vaccine also includes live attenuated mumps virus, it is possible that the measles vaccine is not the sole cause of these cases. SNHL associated with vaccination ranges in severity, can be bilateral or unilateral, and has been reported in both pediatric and adult populations. In some of these patients, symptoms such as fever, rash, headache, and ataxia have been reported after vaccination and prior to onset of hearing loss, consistent with the possibility that hearing loss is the result of vaccination-induced encephalitis ([@bibr7-2331216514541361]; [@bibr13-2331216514541361]). A review by the Institute of Medicine concluded that while hearing loss due to the measles vaccine strain was possible, there was insufficient evidence to make conclusions regarding a causal relationship ([@bibr106-2331216514541361]).

Postexposure prophylaxis is through the use of intramuscularly administered measles immune globulin for infants aged 0 to 6 months and in older immunocompetent people. In pregnant woman without evidence of measles immunity and in severely immunocompromised patients, the measles immune globulin should be administered intravenously ([@bibr72-2331216514541361]). Treatment for measles infection is supportive, including intravenous fluids for dehydration and diarrhea. Secondary infections, including pneumonia, can occur and should be treated promptly ([@bibr92-2331216514541361]).

Treatment of hearing loss resulting from measles depends on the degree and type of hearing loss noted. Hearing aids can be used by patients with mild to moderate SNHL, while cochlear implantation is effective for patients with severe to profound SNHL ([@bibr71-2331216514541361]).

Measles infection has been hypothesized to cause otosclerosis, which causes stapes fixation and subsequent CHL as well as SNHL due to the formation of abnormal foci of bone remodeling in the middle and inner ear. Measles antigens have been identified within otosclerotic lesions, and histological and polymerase chain reaction studies of otosclerotic stapes footplates are suggestive of measles infection ([@bibr58-2331216514541361]). Rates of otosclerosis are higher in patients who have not been vaccinated against measles ([@bibr80-2331216514541361]). Patients with otosclerosis can be treated with either hearing amplification or stapedotomy for their conductive loss and with hearing aids for SNHL. For patients with severe SNHL from otosclerosis, cochlear implantation or stapedotomy for far advanced otosclerosis plus a postoperative hearing aid can rehabilitate hearing ([@bibr98-2331216514541361]).

Varicella Zoster Virus {#sec11-2331216514541361}
----------------------

VZV is a double-stranded enveloped DNA virus of the *Herpesviridae* family. VZV is a highly contagious virus that is transmitted either by droplets from coughing or sneezing of actively infected individuals or by direct contact with fluid from herpetic vesicles. VZV-infected patients are infectious from 2 days prior to appearance of the viral rash until after all the vesicles have crusted. VZV first causes a primary infection that, when symptomatic, manifests with fever, an erythematous macular rash, and pustules (chickenpox). In some individuals, the primary infection is asymptomatic. The virus can subsequently remain latent in neurons in various parts of the body for an extended period, reactivating years later. Symptoms of VZV reactivation (e.g., zoster or shingles) include both systematic symptoms (fever and malaise) as well as local symptoms (severe pain and a vesicular rash) that are limited to the area innervated by the neurons in which the virus reactivated. Risk factors for viral reactivation include age \>50 years, pregnancy/postpartum states, and immunocompromise ([@bibr57-2331216514541361]; [@bibr112-2331216514541361]).

Reactivation of latent VZV within the geniculate ganglion causes Ramsay Hunt syndrome or HZO through the development of geniculate ganglionitis and inflammation of the facial nerve. Eighth nerve involvement results from transfer of the virus from the nearby geniculate ganglion or directly from the facial nerve within the internal auditory canal. Symptoms include facial nerve paralysis, herpetic vesicles, severe otalgia, SNHL (24% of affected patients), tinnitus (48%), and vertigo (30%; [@bibr112-2331216514541361]; [Figure 3](#fig3-2331216514541361){ref-type="fig"}). Additional symptoms such as ipsilateral loss of lacrimation and impaired sense of taste in the ipsilateral two thirds of the tongue result from damage to the facial nerve. Erythematous vesicles that ultimately erupt and crust can typically be seen on the pinna, external auditory canal, tympanic membrane, hard palate, and tongue ([@bibr57-2331216514541361]). Rarely, patients can present with all of the signs and symptoms of HZO without a herpetiform rash (zoster sine herpete; [@bibr112-2331216514541361]). Although the facial, trigeminal, and vestibular nerves are most commonly affected, cases have been reported involving the glossopharyngeal and vagus nerves with resulting dysphagia and hoarseness ([@bibr65-2331216514541361]). Figure 3.Herpes zoster oticus, with crusted vesicles on the face in the left V2 distribution and vesicles and swelling of the left tongue.Source: Clinical photograph used with permission from Braverman Uri, and Greenberg (2000).

SNHL is unilateral and can range from a mild, high frequency loss to profound; however, it is usually mild to moderate. Occasionally, SNHL can occur suddenly as the first manifestation of HZO, and so must be included in the differential diagnosis of SSNHL ([@bibr124-2331216514541361]). Patients with HZO have been found to have ABR changes consistent with both cochlear and retrocochlear dysfunction ([@bibr1-2331216514541361]).

The diagnosis of HZO is usually made based on history and physical examination. Enhancement of the seventh and eighth cranial nerves on gadolinium-enhanced, T1-weighted MRI can be observed ([@bibr38-2331216514541361]). Hemorrhage of the cochlear nerve and destruction of the apex of the organ of Corti have been reported. Temporal bone studies of affected individuals have shown loss of geniculate ganglion cells with neuronal swelling and chromatolysis, perivascular lymphocytic infiltrates, neural demyelination, and axonal loss ([@bibr3-2331216514541361]).

Hearing loss from HZO may improve following treatment, while facial nerve recovery is reported less frequently ([@bibr83-2331216514541361]; [@bibr124-2331216514541361]). Current therapy for HZO involves high doses of both antiherpetic agents and corticosteroids. In one retrospective study of treatment outcomes, facial nerve recovery from HZO occurred in 75% of patients in whom therapy with prednisone and acyclovir was initiated within 72 hr of onset of symptoms. If treatment was initiated before 10 days of onset of HZO, 52% recovered facial function to House--Brackmann grade I. In this study, 22 of 80 patients complained of hearing loss, and of those, 12 patients were monitored with repeated audiograms. Complete hearing recovery was noted in six patients, near complete in three, and no improvement in six ([@bibr77-2331216514541361]). Topical lidocaine or gabapentin can be used to alleviate otalgia. Diazepam has been used to treat vertigo associated the viral labyrinthitis in HZO ([@bibr78-2331216514541361]).

Negative prognostic factors for hearing recovery in HZO include older age, male gender, the presence of vertigo, and hearing impairment within speech frequencies ([@bibr124-2331216514541361]). High-frequency SNHL indicates a better prognosis for complete recovery. The severity of facial nerve paralysis does not necessarily correlate with the severity or prognosis of auditory and vestibular symptoms ([@bibr38-2331216514541361]).

Control of primary varicella infection may decrease the incidence of HZO. Prior to the advent of vaccination for varicella, chickenpox was an extremely common childhood disease with an annual incidence of 15 to 16 per 1,000 population. The U.S. CDC recommends vaccination of children using one of two licensed vaccines. VARIVAX, a single-antigen live-attenuated varicella vaccine, has been available in the United States since 1995 for use in healthy patients aged 12 months and older. A second vaccine, ProQuad (MMRV), includes the live-attenuated antivaricella vaccine as well as the MMR vaccine. These vaccines are thought to reduce the incidence of primary VZV infection by up to 96%. Recommendations include two doses of the vaccine, the first at 12 to 15 months of age and the second at age 4 to 6 years. For teens without evidence of immunity, the recommendations include two doses of VARIVAX separated by 4 to 8 weeks between doses. Because the vaccines include live-attenuated virus, they should not be administered to patients with decreased humoral immunity or to pregnant women. However, these vaccines can be administered to patients with HIV and breastfeeding mothers ([@bibr67-2331216514541361]). Accidental VZV exposure of immunocompetent adults and children who do not have serologic evidence of immunity to varicella is countered by administration of VARIVAX; patients with impaired B-cell immunity should be treated with intravenous antivaricella immunoglobulin following VZV exposure (CDC, 2012).

Prevention of VZV reactivation is also possible via immunization with Zostavax, a live-attenuated antivaricella vaccine that currently is recommended in the United States for patients aged 50 years and older (CDC, 2011). This vaccine utilizes the same attenuated strain as the VARIVAX and MMRV vaccines but at a higher potency. Fifteen percent to 30% of individuals who were infected with VZV experience reactivation later in life (up to 4.2 per 1,000 U.S. population); Zostavax decreases this incidence by 50% ([@bibr46-2331216514541361]). While the direct impact of varicella immunization on HZO has not been measured, presumably the incidence of these cases will also decrease.

Permanent hearing impairment occurs in about 5% of cases of HZO ([@bibr77-2331216514541361]; [@bibr124-2331216514541361]). In these cases, SNHL results from damage to both the cochlea and more proximal auditory pathways ([@bibr1-2331216514541361]; [@bibr54-2331216514541361]). Nonpharmacological treatment is focused on the use of hearing aids to remediate mild to moderately severe SNHL.

Mumps {#sec12-2331216514541361}
-----

The mumps virus is an enveloped single-stranded RNA virus that belongs to the paramyxovirus family, which also includes measles. Mumps is transmitted through infected respiratory secretions and is highly contagious ([@bibr43-2331216514541361]). While mumps is one of the most common causes of acquired SNHL, its incidence varies greatly between studies. Estimates of the incidence of hearing loss following mumps infection range from 1 per 1,000 to 1 per 30,000 to as high as 3 per 100 in the 1984 Israeli epidemic ([@bibr47-2331216514541361]; [@bibr56-2331216514541361]). Differences in vaccination practices between nations may underlie this variance in SNHL. For instance, [@bibr47-2331216514541361] have reported an incidence of 0.1% in Japan, where measles--rubella vaccine was more commonly administered than the MMR.

Initially, mumps presents with symptoms of a flu-like illness, followed by bilateral swelling of the parotid glands ([@bibr29-2331216514541361]). Mumps can additionally cause SNHL, pancreatitis, orchitis, oophoritis, and infertility ([@bibr99-2331216514541361]). Aseptic meningitis and encephalitis can also occur, and their presence increases the risk of SNHL ([@bibr56-2331216514541361]). Mumps increases the risk of spontaneous abortion if acquired during the first trimester of gestation. However, mumps is not believed to cause congenital abnormalities ([@bibr43-2331216514541361]).

The diagnosis of mumps can usually be made by the history and physical examination. Confirmation of the diagnosis is obtained through salivary anti-IgM testing ([@bibr43-2331216514541361]).

SNHL tends to occur suddenly 4 to 5 days after the onset of flu-like symptoms and parotitis ([@bibr45-2331216514541361]). Typically, hearing loss is unilateral and reversible but can be severe and permanent ([@bibr29-2331216514541361]; [@bibr47-2331216514541361]). [@bibr32-2331216514541361] calculated that permanent profound hearing loss occurred in 0.05 of 1,000 cases in patients who had not been vaccinated. Temporal bone studies of patients with mumps SNHL demonstrate nonspecific pathology and are difficult to differentiate from studies of patients with rubella or measles ([@bibr128-2331216514541361]). The virus has been detected in both endolymph and perilymph ([@bibr56-2331216514541361]). Proposed mechanisms of SNHL include atrophy of hair cells in the organ of Corti and stria vascularis, and damage to the myelin sheath around the vestibulocochlear nerve ([@bibr56-2331216514541361]; [@bibr71-2331216514541361]; [@bibr128-2331216514541361]). Brainstem regions may also be involved ([@bibr118-2331216514541361]). Reversible vestibular dysfunction has also been reported in patients with mumps, suggesting that the eighth nerve is involved in the pathology because the utricle, saccule, and semicircular canals are not affected ([@bibr71-2331216514541361]; [@bibr118-2331216514541361]).

The risk of SNHL following mumps infection is not correlated with severity of the infection or presence of parotitis ([@bibr45-2331216514541361]). Asymptomatic cases of mumps can result in sudden SNHL, as demonstrated by positive antimumps IgM antibodies ([@bibr47-2331216514541361]; [@bibr81-2331216514541361]).

The MMR vaccine, introduced in 1949, has drastically reduced the incidence of mumps. Despite the availability of an effective vaccine, several recent outbreaks have occurred, including a 2005 epidemic of 56,000 cases in the United Kingdom among young adults who did not receive adequate immunization ([@bibr43-2331216514541361]; [@bibr99-2331216514541361]). The epidemiology of recent cases differs from that seen in the pre-MMR era, as most cases are observed in patients between 15 and 24 years, rather than in younger children ([@bibr99-2331216514541361]). Today, three doses of MMR vaccine are recommended for mumps prevention---the first at one dose at age 12 to 15 months, the second at 4 to 6 years of age, and the third dose in the late teens/early twenties. Because mumps vaccine contains live, attenuated virus, it is not recommended for severely immunocompromised patients, although current guidelines recommend MMR vaccination for patients with HIV as long as they do not fall into the severely immunocompromised category ([@bibr72-2331216514541361]). Recent outbreaks of mumps have occurred despite vaccination, mainly associated with patients who had received only two doses of the vaccine and who were in crowded conditions, such as densely populated schools. In the 2006 outbreak in the United States, 63% of those affected had received two doses of the mumps vaccine. Eleven out of the 4,039 patients who contacted mumps developed unilateral or bilateral severe to profound SNHL. Of the 10 patients with hearing loss with complete data, none developed permanent hearing loss, suggesting that vaccination may limit the number of patients with mumps who develop permanent severe hearing impairment ([@bibr24-2331216514541361]).

There is no specific treatment against mumps virus, so interventions are mostly supportive ([@bibr43-2331216514541361]). For treatment of SNHL related to mumps, hearing aids can be utilized for mild to severe cases. In severe bilateral cases of SNHL, cochlear implantation has been shown to be efficacious ([@bibr111-2331216514541361]; [@bibr123-2331216514541361]).

West Nile Virus {#sec13-2331216514541361}
---------------

West Nile virus (WNV) is a member of the Flaviviridae family which also includes dengue and yellow fever virus. WNV, like other members of this viral family, has a single-stranded RNA genome and is transmitted by an insect vector ([@bibr48-2331216514541361]). Viral transmission of WNV typically occurs through mosquito bites, but may also be acquired congenitally, through breastfeeding, or through blood transfusions from infected individuals. WNV was initially identified in Uganda in 1940 and is most prevalent in Africa and the Middle East. WNV infection was not seen in the United States until 1999, when an outbreak occurred in New York City. Since that initial outbreak, instances of WNV have been reported throughout the East Coast and the midwestern United States ([@bibr48-2331216514541361]).

Only 20% of WNV infections are symptomatic, and most commonly present with a flu-like illness ([@bibr48-2331216514541361]). However, neurological complications, such as meningitis, encephalitis, and acute flaccid paralysis, occur in less than 1% of cases. These manifestations are more common in elderly or immunocompromised patients. In most cases, the severe neurologic complications eventually resolve with only supportive treatment, although some patients may suffer from persistent flaccid paralysis ([@bibr96-2331216514541361]).

Hearing loss resulting from WNV infection is extremely rare. Similar to other neurologic symptoms, hearing loss is also reported more frequently in immunocompromised patients and often recovers spontaneously ([@bibr53-2331216514541361]; [@bibr70-2331216514541361]). However, at least one case of SNHL in a WNV-infected, immunocompetent man did not resolve, leaving this patient with a permanent downsloping moderate to severe SNHL ([@bibr16-2331216514541361]).

There is no currently Food and Drug Administration-approved vaccine against WNV, although efforts to approve an inactivated WNV vaccine are ongoing. Prevention of WNV is focused on mosquito control programs because bites from infected mosquitoes are the most common route of infection ([@bibr48-2331216514541361]). There is also no specific treatment approved for WNV-infected patients. Ribavarin, interferon alpha 2 b, and intravenous immunoglobulin have been used for patients with severe neurological manifestations of WNV on a compassionate basis, but none of these treatments have been proven in clinical trials ([@bibr48-2331216514541361]).

Conclusion {#sec14-2331216514541361}
==========

A number of viral infections can cause hearing loss. A baseline knowledge of these viruses is critical in the recognition of their involvement in hearing loss in affected patients. Because some of these infections and the hearing loss that they cause can be treated with specific therapy, knowledge of these entities becomes even more important in the evaluation and management of patients with hearing loss. Hearing health care providers may encounter frequent questions from parents of children with hearing loss, questioning whether specific viral infections or vaccinations for these viruses have caused their child's hearing loss.

In this review, we have discussed some of the more commonly known viral causes of hearing loss as well as a few emerging viral infections that ultimately may be shown to be frequent causes of deafness. Some cause congenital hearing loss due to infection of the fetus in utero. Others cause hearing loss as a result of infection in childhood or adulthood. Hearing loss following viral infection is often sensorineural, although it may be mixed (CMV, measles) or conductive (measles). Auditory system damage is typically intracochlear; however, some viruses can affect the auditory brainstem as well. Mechanisms of injury to the peripheral auditory system can include direct viral damage to the organ of Corti, stria vascularis, or spiral ganglion; damage mediated by the patient's immune system against virally expressed proteins (CMV); and immunocompromise leading to secondary bacterial infection of the ear (HIV, measles). Hearing loss due to HZO or CMV infection can be treated medically with stabilization or improvement in hearing thresholds. Common childhood vaccines can prevent several of the viral infections discussed within this review and should be recommended to patients and parents. The incidence of hearing loss following vaccination with live-attenuated virus vaccines, such as the MMR and MMRV, is extremely rare. Rehabilitation of hearing loss due to other viruses typically involves hearing aids, with cochlear implantation for patients with severe to profound hearing loss.
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[^1]: *Note.* CHL = conductive hearing loss; CMV = cytomegalovirus; HAART = highly active antiviral therapy (for HIV); HL = hearing loss; HSV = herpes simplex virus (listed values for type I); IVIg = intravenous immunoglobulin; MMR = measles, mumps, rubella vaccine; Rx = treatment; SNHL = sensorineural hearing loss; VZV = varicella zoster virus; WNV = West Nile virus.

[^2]: *Note.* CMV = cytomegalovirus; HSV = herpes simplex virus; LCMV = lymphocytic choriomeningitis virus; VZV = varicella zoster virus; WNV = West Nile virus.

[^3]: Rubeola is also hypothesized to cause otosclerosis via stimulation of abnormal osteoblastic activity in endochondral bone of the inner ear.
